Microplastics and Nanoplastics: Impacts on Female Reproductive Health, Ovarian Function, and Genitourinary Disorders

Abstract  Microplastics and nanoplastics (MNPs) are detected in ovarian tissue, follicular fluid, placenta, and the female genitourinary tract. Exposure is linked to ovarian toxicity, hormonal imbalance, reduced fertility, and increased risk of endometriosis and other GU disorders through oxidative stress, inflammation, and endocrine disruption. This perspective examines the mechanisms and proposes interaction-mediated therapeutic strategies under the Cythera Bio platform as targeted interventions. This paper is also available at: https://doi.org/10.5281/zenodo.19751747

Figure 1. Biomonitoring and Emerging Therapeutic Opportunities for Women’s Environmental Reproductive Health. Left panel illustrates scalable urine-based monitoring as a practical tool for longitudinal exposure assessment, decentralized research, and comparison of healthy versus clinically affected populations. Right panel depicts future mitigation strategies including interaction-mediated sequestration of particulate burden, targeted delivery of protective compounds, and precision intervention approaches for reproductive and genitourinary health.

1. Exposure PathwaysWomen are exposed via ingestion, inhalation, and potentially transdermal routes. Nanoplastics can cross the blood-follicular and placental barriers, accumulating in reproductive tissues.  Although larger microplastics receive greater public and scientific attention, nanoplastics likely constitute a more biologically consequential category. Their smaller size enables deeper penetration into tissues, broader systemic distribution, and more efficient translocation across delicate physiological barriers.

2. Mechanisms of Toxicity

• Oxidative stress and ROS damage oocytes and granulosa cells.

• Chronic inflammation alters ovarian reserve and endometrial receptivity.

• Plastic additives (BPA, phthalates) act as xenoestrogens, disrupting estrogen/progesterone balance and contributing to endometriosis and PCOS-like phenotypes.

• Z-Model surface-area effects amplify toxicity at low doses.

Figure 2. Potential Effects of Microplastics and Nanoplastics on Female Reproductive and Genitourinary Health. Conceptual overview of major exposure routes including ingestion and inhalation, with illustrative distribution to ovarian tissue, endometrium, placenta, and the genitourinary tract. Proposed biological effects include oxidative stress, inflammation, endocrine disruption, impaired follicular function, and altered reproductive outcomes. These pathways are presented as emerging mechanisms requiring continued investigation.

3. Clinical and Experimental Evidence Animal and in-vitro studies show reduced follicle count, impaired ovulation, and increased miscarriage risk; emerging human data link higher MNP burden to lower fertility outcomes.

4. Biomonitoring and the Role of Scalable Urine Testing in Female Reproductive and Genitourinary Health

A key challenge in assessing the impact of microplastics and nanoplastics on women’s reproductive and genitourinary health is the absence of practical, scalable tools for routine and ongoing monitoring. Most existing research depends on small study populations, complex laboratory techniques, or isolated single measurements that fail to reflect how exposures evolve over time.

Urine-based testing offers a promising, non-invasive solution for stratifying exposure levels, tracking changes longitudinally, and comparing individuals with optimal reproductive health to those affected by infertility, diminished ovarian reserve, endometriosis, PCOS, recurrent pregnancy loss, and other genitourinary conditions. Repeated measurements can reveal potential environmental and occupational contributors, geographic patterns, treatment effectiveness, and direct associations between plastic particle burden and reproductive outcomes.

Through the ecotera health platform, a scalable urine testing system is currently under development to support research, clinical monitoring, and convenient at-home sample collection. These tools have the potential to significantly advance women’s health research, strengthen preventive strategies, and enable more precise, personalized approaches in reproductive medicine and genitourinary care.

4. Therapeutic OpportunitiesInteraction-mediated aggregation reduces MNP translocation and reactive surface area, protecting ovarian and endometrial tissues. Cythera Bio’s LNP platform (S1P-targeted, AI-identified natural compounds) can deliver combined anti-inflammatory, antioxidant, and MNP-binding effects to preserve reproductive health. This approach is particularly relevant for hormone-sensitive GU conditions and aligns with your longevity/space-medicine focus.

5. Conclusion MNPs pose under-recognized risks to female fertility and GU health. Interaction-mediated therapeutics offer a biologically precise strategy that complements your existing detection and mitigation portfolio.

Keywords: microplastics, nanoplastics, female fertility, ovarian toxicity, endometriosis, endocrine disruption, interaction-mediated mitigation

Representative Citations

1. Cui Y, et al. PET microplastics disrupt HER-2 signaling and ovarian function in breast/ovarian cancer models. Environ Sci Technol. 2023.

2. Chen Y, et al. Polystyrene nanoparticles alter ovarian tumor microenvironment and hormone signaling. J Hazard Mater. 2024.

3. Li S, et al. Microplastics induce ovarian toxicity and reduce follicle count in mice. Environ Pollut. 2022.

4. Ding Y, et al. Nanoplastics exacerbate oxidative stress in ovarian granulosa cells. Sci Total Environ. 2023.